Emeline Sarot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emeline Sarot has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Louis Buscail
Department of Gastroenterology and Pancreatology, CHU Rangueil and University of Toulouse, Toulouse, France
16 shared publications - Pierre Cordelier
Université de Toulouse, CNRS, Inserm, CRCT, Toulouse, France
16 shared publications - Vera Pancaldi
Université de Toulouse, INSERM, CNRS, CRCT, Toulouse, France
16 shared publications - Abdessamad El Kaoutari
Aix Marseille Univ, CNRS, Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
15 shared publications - Adele Nevot
Centre de Recherches en Cancerologie de Toulouse, CRCT, Universite de Toulouse, Inserm, CNRS, Toulouse, France
15 shared publications - Audrey Francès
Team Therapeutic Innovation in Pancreatic Cancer, Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France
15 shared publications
Latest Publications
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs